(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug last month and lower-than-expected sales figures from Eli Lilly for two ...

The best way to lose and keep off belly fat is by losing weight gradually through diet, sleep, and exercise choices you can maintain. All exercise will help you burn excess fat around your body ...

Pixar Animation Studios has released the trailer for its new series "Win Or Lose." Will Forte, Rosie Foss, Josh Thomson, Milan Elizabeth Ray, Rosa Salazar, Dorien Watson, Izaac Wang, Chanel ...

It might feel embarrassing to lose Alonso to a lowly team like the Angels, but making sound financial decisions is important even for a team with a sky-high payroll. The Mets are holding firm on ...

The patients had no weight loss plateau and up to 99 per cent of them lost more than 5 per cent of their body weight. More recently, Metsera announced the Phase IIa results for its MET-097i candidate.